The retinoblastoma protein pathway in cell cycle control and cancer

Experimental Cell Research

Volumn 237, Issue 1, 1997, Pages 1-6

  Bartek, Jiri ^a   Bartkova, Jirina ^a   Lukas, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA PROTEIN;

CANCER; CARCINOGENESIS; CELL CYCLE; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0031586604     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1997.3776     Document Type: Article

References (51)

1. 1. Weinberg, R. A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
2. 2. Bartek, J., Bartkova, J., and Lukas, J. (1996). The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol. 8, 805-814.
3. 3. Strauss, M., Lukas, J., and Bartek J. (1995). Unrestricted cell cycling and cancer. Nature Med. 1, 1245-1246.
4. 4. Wang, J. Y. J. (1997). Retinoblastoma protein in growth suppression and death protection. Curr. Opin. Genet. Dev. 7, 39-45.
5. 5. Herwig, S., and Strauss, M. (1997). The retinoblastoma protein: A master regulator of cell cycle, differentiation and apoptosis. Eur. J. Biochem. 246, 581-601.
6. 6. Ikeda, M. A., Jakoi, L., and Nevins, J. R. (1996). A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiarion. Proc. Natl. Acad. Sci. USA 93, 3215-3220.
7. 7. Sherr, C. J. (1994). G1 phase progression: Cycling on cue. Cell 79, 551-555.
8. 8. Sherr, C. J. (1996). Cancer cell cycles. Science 274, 1672-1677.
9. 9. Sherr, C. J., and Roberts, J. M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9, 1149-1163.
10. 10. Harper, J. W., and Elledge, S. J. (1996). Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6, 56-64.
11. 11. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Bartek J. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumor suppressor p16. Nature 375, 503-506.
12. 1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15, 2600-2611.
13. 13. Herrera, R. E., Sah, V. P., Williams, B. O., Mäkelä T. P., Weinberg, R. A., and Jacks T. (1996). Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol. Cell. Biol. 16, 2402-2407.
14. 14. Koh, J., Enders, G. H., Dynlacht, B. D., and Harlow, E. (1995). Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375, 506-510.
15. 15. Connel-Crowley, L., Harper, J. W., and Goodrich, D. W. (1997). Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8, 287-301.
16. 16. Lukas, J., Bartkova, J., and Bartek, J. (1996). Convergence of mitogenic signalling cascades from diverse classes of receptors on the cyclin D/cdk-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16, 6917-6925.
17. 17. Mann, D. J., Higgins, T., Jones, N. C., and Rozengurt, E. (1997). Differential control of cyclins D1 and D3 and the cdk inhibitor p27 by diverse signalling pathways in Swiss 3T3 cells. Oncogene 14, 1759-1766.
18. 18. Assoian, R. K. (1997). Anchorage-dependent cell cycle progression. J. Cell Biol. 136, 1-4.
19. 19. LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11, 847-862.
20. 20. Hannon, G. J., and Beach, D. (1994). p15INK4b is a potential effector of TGFβ induced cell-cycle arrest. Nature 371, 257-261.
21. 21. L'Allemain, G., Lavoie, J. N., Rivard, N., Baldin, V., and Pouyssegur, J. (1997). Cyclin D1 expression is a major target of the cAMP-induced inhibition of cell cycle entry in fibroblasts. Oncogene 14, 1981-1990.
22. 22. Hansen, R., and Oren M. (1997). p53: From inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7, 46-51.
23. 23. Kara, E., Smith, R., Parry, D., Tahara, H., Stone, S., and Peters, G. (1996). Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859-867.
24. 24. Serrano, M., Lee, H. W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-37.
25. 25. Hall, M., and Peters, G. (1996). Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 68, 67-108.
26. 26. Wölfel, Y., Hauser, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K. H., and Beach, D. (1995). Ap16INK4a-insensitive cdk4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284.
27. 27. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. (1995). 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1, 686-692.
28. 28. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhum, C., Shaw, Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. (1997). Decreased levels of the cell-cycle inhibitor p27 Kip1 protein: Prognostic implications in primary breast cancer. Nature Med. 3, 227-230.
29. 29. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Milburn Jessup, J., and Pagano, M. (1997). Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. 3, 231-234.
30. 30. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. (1997). Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 3, 222-225.
31. 31. Bartkova, J., Lukas, J., Strauss, M., and Bartek, J. (1995). Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10, 775-778.
32. 32. Welcker, M., Lukas, J., Strauss, M., and Bartek, J. (1996). Enhanced protein stability: A novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells. Oncogene 13, 419-425.
33. 33. Zhang, P., Liegeois, N. J., Wong, C., Finegold, M., Hou, H., Thompson, J. C., Silverman, A., Harper, J. W., DePinho, R. A., and Elledge, S. J. (1997). Altered cell differentiation and proliferation in mice lacking p57 indicates a role in Beckwith-Wiedemann syndrome. Nature 387, 151-158.
34. 34. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
35. 35. Bartkova, J., Lukas, J., Guldberg, P., Alsner, J., Kirkin, A., Zeuthen, J., and Bartek, J. (1996). The 'p16-cyclin D/CDK4-pRb' pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56, 5475-5483.
36. 36. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrendt, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sindransky, D. (1996). High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56, 3630-3633.
37. INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res. 55, 4818-4823.
38. CDKN2B genes in a new B-cell non-Hodgkin's lymphoma cell line (Granta 519). Leukemia 11, 64-72.
39. 39. Savatier, P., Lapillonne, H., van Grunsven, L. A., Rudkin, B. B., and Samarut, J. (1995). Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells. Oncogene 12, 309-322.
40. 40. Lee, M. H., Williams, B. O., Mulligan, G., Mukai, S., Bronson, R. T., Dyson, N., Harlow, E., and Jacks, T. (1996). Targeted disruption of p107: Functional overlap between p107 and Rb. Genes Dev. 10, 1621-1632.
41. 41. Zindy, F., Quelle, D. E., Roussel, M. F., and Sherr, C. J. (1997). Expression of the p16 INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203-211.
42. 42. Resnitzky, D., and Reed, S. I. (1995). Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Moll. Cell. Biol. 15, 3463-3469.
43. 43. Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., Pagano, M. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 15, 2612-2624.
44. 44. Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I., and Bartek, J. (1997). Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev. 11, 1479-1492.
45. 45. Williams, B. O., Remington, L., Albert, D. M., Mukai, S., Bronson, R. T., and Jacks, T. (1994). Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet. 7, 480-484.
46. 46. Mittnacht, S., Paterson, H., Oison, M. F., and Marshall, C. J. (11997) Ras signalling is required for inactivation of the tumor suppressor pRb cell-cycle control protein. Curr. Biol. 7, 219-221.
47. 47. Peeper, D. S., Upton, T. M., Ladha, M. H., Neuman, E., Zalvide, J., Bernsrds, R., DeCaprio, J. A., and Ewen, M. E. (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177-181.
48. 48. de Boer, C. J., Schuuring, E., Dreef, E., Peters, G., Bartek, J., Kluin, P. M., and van Krieken, J. H. J. M. (1995). Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 86, 2715-2723.
49. 49. Michalides, R., van Veelen, N., Hart, A., and Balm, A. (1995). Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 55, 975-978.
50. 50. Roth, J. A., and Cristiano, R. J. (1997). Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 89, 21-39.
51. 51. Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., and Strauss, M. (1997). Adenovirally transferred p16INK4/CDKN2 p53 genes cooperate to induce apoptotic tumor cell death. Nature Med. 3, 313-319.